This article is more than 5 years old. Information may no longer be current.
iStent inject with phaco reduces need for medications
Click Here to Manage Email Alerts
NEW YORK — A greater percentage of glaucoma patients who received two iStent injects in conjunction with phacoemulsification had no need for IOP-lowering medication than patients who received two iStents and underwent cataract surgery, according to a poster presentation at the American Glaucoma Society annual meeting.
The retrospective, investigational, single-center cohort study aimed to compare the ability of the first-generation iStent and second-generation iStent inject (both Glaukos) to reduce medication burden as well as to assess demographic and ocular factors in the two groups.
Two iStents were implanted in 67 eyes, and two iStent injects were implanted in 67 eyes. At baseline, patients in both groups had IOP in the mid-teens and were on two classes of medications.
At final follow-up, 49% of iStent eyes and 64% of iStent inject eyes were on no medications.
“We found that over a mean follow-up time between 270 and 370 days, medications were reduced more significantly in the [iStent inject] group ... compared to the [iStent] group. The IOP reduction was modest in both sets of patients,” poster author Jithin Yohannan, MD, MPH, told Healio.com/OSN.
Furthermore, success of medication reduction with either the iStent or the iStent inject was increased if the patient was female or white and if the patient had mild rather than moderate glaucoma. – by Robert Linnehan
Reference:
Yohannan J, et al. Intermediate-term outcome of iStent and iStent inject in combination with phacoemulsification. Presented at American Glaucoma Society annual meeting; Feb. 28 to March 4, 2018; New York.
Disclosure: Yohannan reports no relevant financial disclosures.